JDD February 2024 Issue Highlights
Explore the February 2024 issue of the Journal of Drugs in Dermatology! Discover groundbreaking research on topics such as novel treatments for melasma, advancements in psoriasis management, gene expression profile (GEP) testing for squamous cell carcinoma, pediatric vitiligo, and many more! Stay ahead of the curve with the latest insights from leading dermatology experts. Straight from the Editor …
Explore the February 2024 issue of the Journal of Drugs in Dermatology! Discover groundbreaking research on topics such as novel treatments for melasma, advancements in psoriasis management, gene expression profile (GEP) testing for squamous cell carcinoma, pediatric vitiligo, and many more! Stay ahead of the curve with the latest insights from leading dermatology experts. Straight from the Editor … 
Stylecaster recently posted an online article about psychodermatology. How do the mind and skin influence each other? What do we now know and what questions are still unanswered? How can dermatology clinicians best counsel their patients when the mind-skin connection is at work?
For expert advice, I reached out to Steven Daveluy, MD, FAAD, associate professor and program director at Wayne St … 
At the 2023 Skin of Color Update Conference, attendees had the exciting opportunity to listen to Dr. George Han, MD, PhD, from Northwell Health in New York, discuss the prevalence and characteristics of certain skin conditions, primarily in Asian populations. His lecture highlighted the differences in the presentation, genetics, and treatment responses among Asians compared to other ethnic groups … 
Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that in gel form is FDA approved for AIDs-related localized cutaneous Kaposi’s sarcoma (KS)1. As compared to other topical retinoids, alitretinoin is unique in that it binds to all known intracellular retinoid receptors (RARs and RXRs), allowing it to exert anti-proliferative and apoptotic effects, particularly usefu … 